摘要
目的研究二甲双胍联合达格列净或沙格列汀治疗2型糖尿病的疗效及对内脏脂肪、脂代谢的影响。方法选择2017年3月—2019年3月该院收治的90例二甲双胍单药治疗后血糖不达标2型糖尿病患者,随机分为接受二甲双胍联合达格列净治疗的观察组、二甲双胍联合沙格列汀治疗的对照组,比较两组降糖效果、内脏脂肪、脂代谢指标的差异。结果治疗后6个月,两组患者的空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)均显著降低,差异有统计学意义(P<0.05),且两组间FPG、2 hPG、HbA1c比较,差异无统计学意义(P>0.05),观察组患者心外膜脂肪组织厚度(EAT)、肝脏脂肪含量(LFC)、胰岛素抵抗指数(HOMA-IR)及空腹胰岛素(FIns)、胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)含量明显降低,差异有统计学意义(P<0.05),而TG、HDL-C含量比较,差异无统计学意义(P>0.05),对照组患者的EAT、LFC、HOMA-IR及FIns、TG、TC、LDL-C、HDL-C含量比较,差异无统计学意义(P>0.05)。结论二甲双胍联合达格列净治疗2型糖尿病的降糖效果与二甲双胍联合沙格列汀相当且在改善胰岛素抵抗、减少内脏脂肪、调节脂代谢中具有优势。
Objective To study the efficacy of metformin combined with dapagliflozin or saxagliptin in the treatment of type 2 diabetes and its influence on visceral fat and lipid metabolism.Methods Selected 90 patients with type 2 diabetes who did not meet the standard of blood glucose after metformin monotherapy treated in this hospital from March 2017 to March 2019.They were randomly divided into an observation group receiving metformin combined with dapagliflozin and a control group receiving metformin combined with saxagliptin.The differences in blood sugar lowering effect,visceral fat,and lipid metabolism between the two groups were compared.Results At 6 months after treatment,the fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG),and glycosylated hemoglobin(HbA1c)of the two groups of patients were significantly reduced,and the difference was statistically significant(P<0.05),and between the two groups compared with FPG,2 hPG,and HbA1c,the difference was not statistically significant(P>0.05).The observation group patients'epicardial adipose tissue thickness(EAT),liver fat content(LFC),insulin resistance index(HOMA-IR)and fasting insulin(FIns),cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)content was significantly reduced,the difference was statistically significant(P<0.05),while TG,HDL-C content comparison,the difference was not statistically significant(P>0.05).There was no significant difference in the content of EAT,LFC,HOMA-IR and FIns,TG,TC,LDL-C,HDL-C in the control group(P>0.05).Conclusion The hypoglycemic effect of metformin combined with dapagliflozin in the treatment of type 2 diabetes is equivalent to that of metformin combined with saxagliptin and has advantages in improving insulin resistance,reducing visceral fat,and regulating lipid metabolism.
作者
许素云
杨秀梅
黄小丽
XU Suyun;YANG Xiumei;HUANG Xiaoli(The Sixth People's Hospital of Huizhou City,Huizhou,Guangdong Province,516211 China)
出处
《糖尿病新世界》
2021年第12期94-97,共4页
Diabetes New World Magazine
关键词
2型糖尿病
达格列净
沙格列汀
胰岛素抵抗
内脏脂肪
脂代谢
Type 2 diabetes
Dapagliflozin
Saxagliptin
Insulin resistance
Visceral fat
Lipid metabolism
